and per share amounts) $ $ $ $
-------------------------------------------------------------------------
REVENUE
Product sales 2,818 1,097 10,359 4,044
Licensing 1,058 2,229 4,786 6,672
Research and development
collaborations 1,217 - 1,217 -
-------------------------------------------------------------------------
5,093 3,326 16,362 10,716
-------------------------------------------------------------------------
EXPENSES
Cost of goods sold
(excluding amortization) 1,012 691 6,716 2,267
Research and development
expenses, net 7,171 2,611 17,088 12,466
Selling, general and
administrative expenses 4,596 4,069 16,048 11,060
Financial expenses 434 644 1,474 2,056
Impairment loss on
long-term investment 874 - 874 -
Depreciation and
amortization 510 430 1,482 1,276
Interest income (810) (1,271) (2,707) (2,277)
Foreign exchange loss (gain) (107) (50) 280 (643)
-------------------------------------------------------------------------
13,680 7,124 41,255 26,205
-------------------------------------------------------------------------
LOSS BEFORE INCOME TAXES (8,587) (3,798) (24,893) (15,489)
Provision for income taxes
Current 508 598 1,710 1,282
Future (64) (35) (64) (71)
-
'/>"/>
| SOURCE Labopharm Inc. Copyright©2007 PR Newswire. All rights reserved |